Latest Sevelamer Stories
~Launches "Keryx Patient Plus" for Reimbursement Support and Patient Access NEW YORK, Dec. 22, 2014 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
Phosphate Binder Combination Use in Dialysis is Low, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs.
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage
Improved Pill Burden Scored Highest in Terms of Delivery Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 22, 2014 /PRNewswire/ -- Decision Resources
High phosphate levels in the blood carry increased heart-related risks, but taking a drug that targets phosphate does not improve cardiovascular measures in patients with mild kidney disease.
Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as strongly effective as once thought, and may cause unexpected harm to blood vessels.